---
title: "Centessa Pharmaceuticals plc (CNTA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CNTA.US.md"
symbol: "CNTA.US"
name: "Centessa Pharmaceuticals plc"
industry: "Biotechnology"
datetime: "2026-05-19T20:28:28.320Z"
locales:
  - [en](https://longbridge.com/en/quote/CNTA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CNTA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CNTA.US.md)
---

# Centessa Pharmaceuticals plc (CNTA.US)

## Company Overview

Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [centessa.com](https://centessa.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: D (0.71)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 207 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.00% |  |
| Net Profit YoY | -11.97% |  |
| P/B Ratio | 12.59 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6133456212.24 |  |
| Revenue | 0.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -57.38% | E |
| Profit Margin | 0.00% | D |
| Gross Margin | 0.00% | E |
| Revenue YoY | -100.00% | E |
| Net Profit YoY | -11.97% | D |
| Total Assets YoY | 21.58% | A |
| Net Assets YoY | 26.18% | A |
| Cash Flow Margin | 83.31% | C |
| OCF YoY | -100.00% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 24.06% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Centessa Pharmaceuticals plc",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-11.97%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "12.59",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6133456212.24",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "0.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-57.38%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-11.97%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "21.58%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "26.18%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "83.31%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "24.06%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -24.47 | 512/386 | - | - | - |
| PB | 12.59 | 400/386 | 12.57 | 10.75 | 5.59 |
| PS (TTM) | 409.03 | - | 276.18 | 218.14 | 142.21 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-08T04:00:00.000Z

Total Analysts: **13**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 23% |
| Overweight | 1 | 8% |
| Hold | 9 | 69% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 39.70 |
| Highest Target | 62.00 |
| Lowest Target | 38.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CNTA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CNTA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CNTA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CNTA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**